Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer

Journal of Clinical Oncology

Volumn 15, Issue 8, 1997, Pages 2800-2806

  Quinn, Charles T ^a   Griener, James C ^a   Bottiglieri, Teodoro ^a   Hyland, Keith ^a   Farrow, Arleen ^a   Kamen, Barton A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE SULFINIC ACID; EXCITATORY AMINO ACID; HOMOCYSTEIC ACID; HOMOCYSTEINE; METHOTREXATE; NEUROTRANSMITTER;

ARTICLE; CEREBROSPINAL FLUID; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HYPERHOMOCYSTEINEMIA; INTRAVENOUS DRUG ADMINISTRATION; LUMBAR PUNCTURE; NERVE CELL NECROSIS; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; SEIZURE; STROKE;

EID: 0030836369     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.8.2800     Document Type: Article

References (44)

1. Jonsson OG, Kamen BA: Methotrexate and leukemia. Cancer Invest 9:53-60, 1991
2. Allen JC, Rosen G, Mehta BM, et al: Leukoencephalopathy following high-dose IV methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 64:1261-1273, 1980
3. Jaffe N, Takaue Y, Anzai T, et al: Transient neurologic disturbances induced by high-dose methotrexate treatment. Cancer 56:1356-1360, 1985
4. Walker RW, Allen JC, Rosen G, et al: Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 4:1845-1850, 1986
5. Kay HE, Knapton PJ, O'Sullivan JP, et al: Encephalopathy in acute leukaemia associated with methotrexate therapy. Arch Dis Child 47:344-354, 1972
6. Quinn CT, Kamen BA: A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Invest Med 44:522-530, 1996
7. Abelson HT: Methotrexate and central nervous system toxicity. Cancer Treat Rep 62:1999-2001, 1978
8. 2 intravenous methotrexate. Pediatr Res 37:151-154, 1995
9. Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate: Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 92:2675-2682, 1993
10. Kane BJ, Kuhn JG, Roush MK: Pentostatin: An adenosine deaminase inhibitor for the treatment of hairy cell leukemia. Ann Pharmacother 26:939-947, 1992
11. Bernini JC, Fort DW, Griener JC, et al: Aminophylline for methotrexate-induced neurotoxicity. Lancet 345:544-547, 1995
12. Refsum H, Helland S, Ueland PM: Fasting plasma homocysteine as a sensitive parameter of antifolate effect: A study of psoriasis patients receiving low-dose methotrexate treatment. Clin Pharmacol Ther 46:510-520, 1989
13. Refsum H, Ueland PM, Kvinnsland S: Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine. Cancer Res 46:5385-5391, 1986
14. Broxson EH, Stork LC, Allen RH, et al: Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusions. Cancer Res 49:5879-5883, 1989
15. Refsum H, Wesenberg F, Ueland PM: Plasma homocysteine in children with acute lymphoblastic leukemia: Changes during a chemotherapeutic regimen including methotrexate. Cancer Res 51:828-835, 1991
16. Rees MM, Rodgers GM: Homocysteinemia: Association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 71:337-359, 1993
17. Malinow MR: Homocyst(e)ine and arterial occlusive diseases. J Intern Med 236:603-617, 1994
18. Clarke R, Daly L, Robinson K, et al: Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 324:1149-1155, 1991
19. Phanthumchinda K, Intragumtornchai T, Kasantikul V: Stroke-like syndrome, mineralizing microangiopathy, and neuroaxonal dystrophy following intrathecal methotrexate therapy. Neurology 41:1847-1848, 1991
20. Yim YS, Mahoney DH, Oshman DG: Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 67:2058-2061, 1991
21. Cuénod M, Grandes P, Zängerle L, et al: Sulphur-containing excitatory amino acids in intercellular communication. Biochem Soc Trans 21:72-77, 1993
22. Griffiths R: The biochemistry and pharmacology of excitatory sulphur-containing amino acids. Biochem Soc Trans 21:66-72, 1993
23. Turski WA: Homocysteic acid: Convulsant action of stereoisomers in mice. Brain Res 479:371-373, 1989
24. Thompson GA, Kilpatrick IC: The neurotransmitter candidature of sulphur-containing excitatory amino acids in the mammalian central nervous system. Pharmacol Ther 72:25-36, 1996
25. Lipton SA, Rosenberg PA: Mechanisms of disease: Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330:613-622, 1994
26. Winick N, Shuster JJ, Bowman WP, et al: Intensive oral methotrexate protects against lymphoid marrow relapse in children with B-precursor acute lymphoblastic leukemia. J Clin Oncol 14:2803-2811, 1996
27. Araki A, Sako Y: Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 422:43-52, 1987
28. Ling BL, Dewaele C, Baeyens WRG: Micro liquid chromatography with fluorescence detection of thiols and disulphides. J Chromatogr 553:433-439, 1991
29. Hyland K, Bottiglieri T: Measurement of total plasma and cerebrospinal fluid homocysteine by fluorescence following high-performance liquid chromatography and precolumn derivatization with o-phthaldialdehyde. J Chromatogr 579:55-62, 1992
30. Vester B, Rasmussen K: High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 29:549-554, 1991
31. McLean AM, Ruggirello DA, Banfield C, et al: Application of a variance-stabilizing transformation approach to linear regression of calibration lines. J Pharm Sci 79:1005-1008, 1990
32. Joseph MH, Davies P: Electrochemical activity of o-phthaladehyde-mercaptoethanol derivatives of amino acids. Application to high performance liquid chromatographic determination of amino acids in plasma and other biological materials. J Chromatogr 277: 125-136, 1983
33. Hyland K, Surtees R: Measurement of 5-methyltetrahydrofolate using HPLC with coulometric electrochemical detection. Pteridines 3:149-150, 1992
34. Blom HJ, Wevers RA, Verrips A, et al: Cerebrospinal fluid homocysteine and the cobalamin status of the brain. J Inherit Metab Dis 16:517-519, 1993
35. Stabler SP, Allen RH, Barret RE, et al: Cerebrospinal fluid methylmalonic acid levels in normal subjects and patients with cobalamin deficiency. Neurology 41:1627-1632, 1991
36. 12 and neuropsychiatric disorders. Nutr Rev 54:382-390, 1996
37. Kamen BA, Nylen PA, Camilla BM, et al: Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. Br J Haematol 49:355-360, 1981
38. Ohmori S, Kodama T, Ikegama T, et al: Unusual sulfur-containing amino acids in the urine of homocystinuric patients: III. Homocysteic acid, homocysteine sulfonic acid, S-(carboxymethylthio)homocysteine, and S-(3-hydroxy-3-carboxy-n-propyl)homocysteine. Physiol Chem Phys 4:286-294, 1972
39. Frauscher G, Karnaukhova E, Muehl A, et al: Oral administration of homocysteine leads to increased plasma triglycerides and homocysteic acid-additional mechanisms in homocysteine-induced endothelial damage. Life Sci 57:813-817, 1995
40. Grieco AJ: Homocystinuria: Pathogenetic mechanisms. Am J Med Sci 273:120-132, 1977
41. Kang SS, Zhou J, Wong PWK, et al: Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 43:414-421, 1988
42. Mandel H, Brenner B, Berant M, et al: Coexistence of hereditary homocystinuria and factor V Leiden - Effect on thrombosis. N Engl J Med 334:763-768, 1986
43. Smolin LA, Benevenga NJ, Berlow S: The use of betaine for the treatment of homocystinuria. J Pediatr 99:467-472, 1981
44. Stampfer MJ, Malinow MR: Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 332:328-329, 1995